<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 331 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page330.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=331">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 331 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 331</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=331"><img src="../thumb/331.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>294 / 2020-04                                                     Endocrine System - 19.1.2 / 19.1.2.1








   (S3) TABS, 45/21.2/0207, 0208, 0209  Special precautions: Lactic acidos., monit. creatinine lev., situat.  Contraindications: Hepat.impairm.incl.pre-treatm. ALT or AST &gt;2,5x
   719643-001: 500 mg, 100, R41,76  where ren.funct.may become imp., incr.CV mortal.assoc., discont.bef.  upper limit of norm., safety in pregn.& lactat.not est., not stud.in pts.
   719644-001: 850 mg, 60, R44,40  admin. iodinat. contrast mat.& 48 hrs.bef.elect.surg., hypoglycaem.  und.18 yrs., NYHA class IV HF
   719645-001: 1 000 mg, 60, R49,92  poss.in comb.sulphonylurea/insul. ther., avoid.consumpt.alcoh.&   Side effects: Hepat.dysfunct., angioed., trem., dizzin., headache,
   Dosage: Admin.in div.dos.with meals. Poss. improv. G/I tol.with slow.  alcoh.cont.meds., poss. dos.adjustm.of anticoag./other anti-diabet.   chills, asthen., periph.oed., naus., flatul., GORD, diarrh., constip., decr.
   dos.incr. Dos.adjustm. based on bld.gluc.aft.10-15 days.   agents, not advis.in dehydrat.condits./ser.infects./ trauma & low calo-  bld. gluc., hypoglycaem., hyperhidros., hepatit., urticar., pancreatit.,
   Adults: Init. 500 mg 3x.dly OR 850 mg/1 000 mg 2xdly.with/aft.food.   rie intake, annual Vit B 12 estimat., stabilis.pts.on ther.with insul.in hosp.  arthralg., loc.exfoliat./blist.
   Good diab.contr.poss.aft.few days but full benef.poss.delay for up to   Drug interactions: Ac.alcoh.intoxicat. incr.lact. acidos.risk, gluco-  Warnings and special precautions: LFT’s prior to init.treatm.&
                                                                               st
   2 wks. Incr. dos.to max.2 550 mg/day if contr inadeq. Poss. dos. reduc.  cortic./beta-2-agonists & diuret. have an inherent hyperglycaem.eff.,   imperat.dur.treatm.at 3 mnthly. interv.dur.1  yr. & periodical.thereaft.,
   once contr.has been achiev. Childr. from 12 yrs & adolesc: Start.  ACE inhibit. may decr.bld.gluc.lev., cimetidine reduc.ren.clear., activ.   discont. if AST/ALT incr.of 3xULN, not a substit. for insul.in insul.req.
   dos. usual.500 mg or 850 mg once dly.dur./aft.meals. Max.recomm.   of warfar.dimin., poss.hypoglycaem.with concom. sulphonylurea,   pts., not for use in type 1 diab., diabet.ketoacidos., lact.intol., ren.
   dos: 2 000  mg dly.in 2-3 div.dos.  malabsorpt.of Vit.B 12 with prolong. use.  impairm., discont.& do not reinit.if jaund./other sympts. suggest.of
   Contraindications: Diabet.ketoacidos./-pre-coma or hist.therof,   liv.dysfunct.dev., NYHA class III HF, poss.sev.arthralg.
   ren.dysfunct./fail., ac.condits. potent. alt.kidn.funct.eg.dehydrat./  SULPHONUR, Specpharm [P/S]  See also MDR page 558.
   sev.infect./ shock/ intravasc.admin.of iodinat.contrast agents, ac./   Glimepiride
   chron.dis.where tiss.hypox.poss.be induc.such as card./resp.fail./  Indications: Type 2 diab.mellit.not control.by diet. & exerc.alone.  GALVUS MET, Novartis &
   rec.MI/shock/pancreatit., chron. liv. dis., hist.of/states assoc.with   (S3) TABS, 41/21.2/0519, 0520, 0521  Vildagliptin 50 mg, metformin HCl 850 mg
   lact.acidos.such as pulm.insuffic., hepat.insuffic., ac.alcoh.intox., al-  710904-001: 1 mg, 30, R63,09  Vildagliptin 50 mg, metformin HCl 1 000 mg
   cohol., safety & effic.in childr.not est., safety in pregn.& lactat.not est.  710905-001: 2 mg, 30, R126,21  Indications: Diet.& exerc.adjunct. in type 2 diab. mellit.pts.who are
   Side effects: Lact.acidos., megaloblast.anaem., GI disturbs., metall.  710906-001: 4 mg, 30, R191,61  already stabilis.with separate vildagliptin & metformin combinat.at
   taste, sev.cholestat.hepatit., abnorm. LFT, hypersens., hypoglycaem.,   Dosage: Indiv.accord.to bld.gluc.lev.at low.dos. to achiev.desir.  same dos., add-on to insul.as adjunct to diet &exerc. in pts. on sta-
   decr.Vit. B 12 & folic acid absorpt.  metabol.contr. Sngl.dly.dos.usual. adeq. to provide metabol.con-  ble dos.of insulin plus separate vildagliptin & metformin combinat.
   Special precautions: Cross.placenta, pass.into breast milk, reduc.  trol over 24 hrs.  at same dos., in combinat. with a sulphonylurea (i.e. triple combinat.
   incid.of lactat.acidos.by assess. assoc. risk fact., discont.& hospitalis.  Init: 1 mg once dly.which may be grad.incr.at interv. of 1-2 wks.by   ther.) as adjunct to diet & exerc. in pts.stabilis. on a separate vildaglip-
   immed.if lact. acidos. suspect., monit.ren.funct.bef.init.ther.& reg.   1 mg-2 mg-3 mg-4 mg-6 mg. Max.dos.8 mg/day. Usual.dly.dos: 1-4 mg   tin, metformin and sulphonylurea combinat.at same dos.
   thereaft.esp.elderly/condits.where ren.funct. impair., discont.ther.  taken bef. a substant.breakf./1st main.meal of the day.  (S3) TABS, 43/21.2/1055, 1056
   bef.intravasc.admin.of iodinat. contrast mat.& reinstit.aft.ren.funct.   Improv.diab.contr.is assoc.with improv.insul. sensitiv. theref.dos.  717636-001: 50/850 mg, 30, R192,93
   contr.regain., discont. 48 hrs.bef.elect.surg./gen.anaesthes.& re-start   reqd.may decr.over time  717636-002: 50/850 mg, 60, R385,89
   not bef.48 hrs., condit.poss.caus.dehydrat. /ser. infects./trauma/low   Contraindications: Sulphonylurea/other sulphonamide hypers-  717637-001: 50/1 000 mg, 30, R192,03
   calorie intake, fast./ malnutrit., hepat.insuffic., avoid.alcoh./alcoh.-  ens., pregn., lactat., imp.liv. funct., mod.to sev.imp.ren.funct., childr.,   717637-002: 50/1 000 mg, 60, R385,89
   cont. meds., more freq.bld.gluc.monit.with concom. glucocortic./  type 1 diab. mellit.  Dosage: Do not exceed max.dly.dos.(100 mg) of vildagliptin  Ad-
   beta-2-agonist/diurets.esp.init., poss. dos. adjustm. with anticoags.,   Side effects: Bld.dyscras., CNS effs., hypoglycaem., signs of adr-  min.with meals.
                                                              Recomm.start.dos: Bas.on pts.current vildagliptin and/or met-
   not recomm.in type 1 diab.mellit.in childr.& adolesc., annual Vit. B 12   energ.excess, GI disturbs., polyuria, imp.hepat.funct., blurr.vis./ ocul.   formin regimen.
   lev. assessm.with contin.ther., concom. sulphonylur., stabil.in hosp.  accomodat.changes esp.at start of treatm., skin reacts., allerg.reacts.
   if concom. insul.admin., contin. diet with reg. carbohydr.distrib. dur.  which may develop into life threaten.reacts.  In combinat.with sulphonylurea/insulin: GALVUS MET dos. should
   day/ energy-restrict.diet in overweight pts.  Special precautions: Incr.CV mortalit.report. with oral sulphony-  prov. vildagliptin dos. as 50 mg 2xdly. (100 mg tot.dly.dos) & a dos.of
   Drug interactions: Incr.lact.acidos.risk with ac. alcoh.intoxicat./in-  lurea antidiabet.esp.in high risk myocard. ischaem.pts., poss.dos.ad-  metform. simil. to dos. already being taken.
   travasc.admin.of iodinat.contrast agents, ACE inhibit.decr.bld.gluc.  justm. with chang.in pts.weight/lifestyle/meds., when substit. use   Contraindications: Ren.dis./dysfunct.with ser. creatin. lev.&gt;1,5 mg/
   lev., reduc.ren. clear. with cimetidine, warfar.activ.dimin., hypogly-  same dos.proced.as for init.dos. recomm. as no exact dos.relation-  dl(males)& &gt;1,4 mg/dl (fem.), hepat. impairm.incl.pre-treatm.ALTor
   caem. with sulphonylur., Vit.B 12 malabsorpt. with longt.use.  ship with other oral antidiabet.agents avail., hypoglycaem.risk incr. in   AST &gt;2,5x upper limit of norm., CHF req.pharmacol.treatm., ac./
                                init.wks.of treatm.theref.monitor.essent., fact. favour. hypoglycaem.,   chron.metabol.acidos.incl.diabet.ketoacidos., safety in pregn.& lactat.
   SANDOZ GLICLAZIDE 80, Sandoz [P/S]  endocr.disords.involv. thyroid/ anter.pituit/adren.glands, when coun-  not est., safety & effic.not est. in pts.und.18 yrs., NYHA class IV HF
   Gliclazide.                  ter-regulat.horm.respons.to hypoglycaem.blunt/ attenuat., convert   Side-effects: Angioed., hepat.dysfunct., hepatit., hypoglycaem.,
   Indications: Non insul.depend.diabet.mellit. where diet.man-  pt.tempor.to insul.to maint. good metabol.control dur.except.stressors.  trem., dizzin., headache, chills, constip., GORD, flatul., periph.oed.,
   agem.alone insuffic.         Drug interactions: Hypoglycaem.with allopurin. / anabol.ster.& an-  urticar., pancreatit., decr.vit.B12 absorpt., lactic acidos., metall. taste,
   (S3) TABS. Z/21.2/197.       drog./ACE inhibit./ disopyramide/ chloramphenicol/sulphonamide/   N&V, diarrh., abdom.pain, loss of appetite, skin reacts., arthralgia.,
   834866-005: 80 mg, 60, R52,25  quinolones/ tetracycl./coumar.derivat./fluoxet./ cyclophospham./   asthen., hyperhidros., loc.exfoliat./blister., abnorm.LFT
   Dosage: Tot.dly.dos.may vary from 40-320 mg in div.dos.with meals.   ifosfamide/trofosfamide/ fenfluramine/ azole antifung./ß-block./   Warnings and special precautions: Tempor. discont.with radiolog.
   Indiv. Init 40-80 mg dly incr.grad.until adeq. contr.achiev.  fenyramidol/ clofibrate/guanethidine/insul.& other oral antidiab./  stud.involv.IV admin.of iodinat. contrast media & only re-instit.aft.norm.
   Contraindications: Chron.liv.dis.incl.that caus. by uncompen.CF   MAOI/para-aminosalicyl. acid/ pentoxifylline (high parenter.dos)/   ren.funct.determ., not a substit.for insul.in insul. req.pts. not for use in
   /alcoh., metab.decompensat.with acidos. & ketos., pre-comatose   phenylbutazone/azapropazone/oxyphenbutazone / probenecid/sul-  type 1 diab./diabet. ketoacidos., monit.ren.funct.& discont.if ren. im-
   states, diab. mellit. complicat.by fev., infect., febr.dis., trauma, pan-  phinpyrazone/tritoqualine.  pairm.pres., excess.alcoh.as alcoh.potent. metformin eff., discont.&
   creatit., gangrene, ser.thyroid/adren.funct. impairm.  Hyperglycaem.with acetazolamide/adrenal.& other sympathomimet./  hospitalise pt.if metabol. acidos.suspect., elderly & reduc.ren.funct.,
   Side effects: GI disturbs., dizzin., weakn., paraesthes., sens.reacts.,   barbitur./corticoster./ diazoxide/diuret./glucagon/isoniazid/protact.   LFT’s prior to init.treatm.& dur.treatm.at 3-mnthly. interv.dur.1  yr.&
                                                                                        st
   skin rash., bld.disords.     laxat./ high dos.nicotin.acid/oestrog.& progestog. /phenothiazines/  periodic.thereaft., discont.if AST/ ALT incr.of 3x ULN persist, discont.
   Special precautions: Incr.CV mortality compar. to treatm.with diet   phenytoin/rifampicin & thyroid hormon., eff.of coumarin deriv. potent./   if jaund./ other signs of liv.dysfunct.devel., lactic acidos.risk fact., con-
   alone/diet & insul., ren impairm., poss.hypoglycaem.dur.combin.ther.  weaken., H 2-recept.antagon./ß-block./ alcoh/ clonidine & reserpine   dits.where ren.funct.may become imp., concom. meds.that affect ren.
   with insul./other diab.agents.   may either potent./ weak. eff., sympatholytic blunt signs of adren-  funct./affect metform. disposit.eg cationic meds., NYHA class III HF,
   Drug interactions: Sulphonamid., salicylat., phenylbutazone, ß-  erg. hypoglycaem. respons.  shock/ac.CHF/ac.MI & condits.characteris. by hypoxaem.have been
   adrenoceptor block.agents, MAOI, chloramphenicol, clofibrate,   assoc.with lact.acidos./ preren.uraem., suspend.treatm.for surg.pro-
   halofenate, ketoconazole, miconazole, cimetidine, dicoumarol & cy-  ced. where food & fluid restrict., annual haematol. monit. & Vit.B12
   clophosphamide may potent.act., eff.dimin.by adrenaline, oestrog.,   measurem., eval.for ketoacidos. &/lact.acidos.if clinic.status of prev.
   thiazide diuret.& corticoster., propranolol and other ß-block.may mask   19.1.2.1  DPP-4 antagonists  control.type 2 diab. pts.change, condits.where bld.gluc.control tempor.
   hypoglycaem. sympts., great.CV mortal.risk with concom. biguanid.  GALVUS (MDR Listing)  lost eg stress./fev./trauma/surg.etc., pts. suscept.to hypoglycaem.effs.
   SANDOZ METFORMIN HCl 500 FC; 850 FC Sandoz [P/S]  GALVUS MET (MDR Listing)  Interactions: Alcoh.intoxicat.incr.lact.acidos. risk., nifedipine incr.
                                                              metform.absorpt./C max/AUC & excret.in urine, cimetidine incr.met-
   Metformin HCl.               ONGLYZA (MDR Listing)         form.plasma/ bld.conc.& AUC, meds.produc.hyperglycaem.may lead
   Indications: Type II diab.mellit where diet fail. esp. if overweight,   to loss of glycaem.contr., furosemide incr. C max & bld.AUC of metform.,
   giv.init.alone/combin.with sulphonylurea/insul.  GALVUS, Novartis &  metform.decr.C max & bld. AUC of furosemide
   (S3) TABS, 28/21.2/0046, 0047  Vildagliptin                See also MDR page 560.
   815225-008: 500 mg, 100, R52,38  Indications: Diet.& exerc.adjunct.to improve glycaem.contr.in adults
   815233-019: 850 mg, 60, R58,73  with type 2 diab.mellit. as add-on ther.combin.with metform./a sulph-  JALRA, Novartis [P/S]
   Dosage: Admin.in div.dos.with/aft.meals.  onylurea /insul.with/-out metformin when diet/ exerc.& sngl.antidiab.  Vildagliptin
   Adults: Init.dos. 500 mg 3xdly adjust.aft.10-15 days or incr.to 850-  agent do not result in adeq.glycaem. control., triple combin.with a   Indications: Diet.& exerc.adjunct.to improve glycaem.contr.in adults
   1 000 mg 2xdly. Grad incr.if necess.to max.3 g dly. Dos.may poss.be   sulphonylurea & metform. when diet/exerc.& dual ther.with these   with type 2 diab.mellit. as add-on ther.combin.with metform./a sulph-
   reduc. once control achiev.  antidiab.agents do not prov adeq. glycaem. control.  onylurea or insul.when diet/exerc.& sngl.antidiab.agent do not result
   Contraindications: Diab.ketoacidos., diabet.pre-coma/ hist.thereof,   (S3) TABS, 41/21.2/0487  in adeq.glycaem.control.
   imp.ren.funct., pancreatit., chron. liv.dis., hist./states assoc.with lactic   715554-001: 50 mg, 28, R179,88  (S3) TABS, 45/21.2/1009
   acidos., card.fail./rec.MI, hypox.assoc.condits., hepat. insuffic., ac.alcoh.  715554-002: 50 mg, 56, R359,78  721592-001: 50 mg, 28, R75,32
   intoxicat./alcoholism, safety & effic. in pregn.& childr.not est., no safe-  Dosage: Indiv.dos.  721592-002: 50 mg, 56, R150,64
   ty info on use dur.lactat., not recomm.for type I diab. mellit.in childr.  Recomm.dos: 50 mg once dly, or 50 mg 2xdly in combinat. with   Dosage: Indiv.dos.
   Side effects: Lactic acidos., megaloblast.anaem., GI disturbs.,   metform/insul.with/-out metformin  Recomm.dos: 50 mg once dly,or 50 mg 2xdly in combinat. with
   metall.taste, ketoacidos., ketonur., sev. cholestat.hepatit., hypers-  In combinat.with a sulphonylurea: 50 mg once dly.admin.in morn.  metform.or insul.,
   ens., hypoglycaem.           Triple combinat.with metform.& a sulphonylurea: 50 mg 2xdly  In combinat.with a sulphonylurea: 50 mg once dly.admin.in morn.
                        S4 JARDIANCE ®  10 mg: Each film-coated tablet contains empagliflozin 10 mg. Reg. No. 48/21.2/1380. S4 JARDIANCE ®  25 mg: Each film-coated tablet contains empagliflozin 25 mg.
                        Reg. No. 48/21.2/0411. For full prescribing information refer to the professional information approved by the Regulatory Authority. Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd,
                        407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100408. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page330.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page326.html">326</a>&nbsp;&nbsp;&nbsp;<a href="page327.html">327</a>&nbsp;&nbsp;&nbsp;<a href="page328.html">328</a>&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>&nbsp;&nbsp;&nbsp;<a href="page330.html">330</a>&nbsp;&nbsp;&nbsp;<a href="page331.html">331</a>&nbsp;&nbsp;&nbsp;<a href="page332.html">332</a>&nbsp;&nbsp;&nbsp;<a href="page333.html">333</a>&nbsp;&nbsp;&nbsp;<a href="page334.html">334</a>&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>&nbsp;&nbsp;&nbsp;<a href="page336.html">336</a>
             </td>
             <td width="35%"><a href="page332.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page332.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
